Neoadjuvant Lenvatinib in Advanced Unresectable Thyroid Carcinoma: Case Series and Literature Review
DOI:
https://doi.org/10.35790/ecl.v13i1.58793Abstract
Abstract: Lenvatinib, a tyrosine kinase inhibitor (TKI), has shown potential as a neoadjuvant therapy for inoperable thyroid cancer (TC). In this case series, we present three patients with unresectable thyroid tumors who responded favorably to lenvatinib treatment. A 60-year-old male with papillary thyroid cancer (PTC) experienced a 60% tumor volume reduction after five months of therapy. A 61-year-old male with medullary thyroid cancer (MTC) saw a 99% reduction after four months of lenvatinib and decrease of serum calcitonin and no residual disease six months after surgery. Lastly, a 67-year-old female with anaplastic thyroid cancer (ATC) showed a 70% tumor reduction and significant symptomatic relief. These cases highlight lenvatinib’s efficacy in reducing tumor size and stabilizing disease, improving surgical outcomes in patients initially deemed inoperable due to locally advanced tumors. Lenvatinib’s antitumor effects, driven by its antiangiogenic properties, suggest its potential as a valuable neoadjuvant treatment option in advanced thyroid cancer.
Keywords: thyroid carcinoma; lenvatinib; case series
References
Grimm D. Recent advances in thyroid cancer research. Int J Mol Sci. 2022;23(9):1-15. Available from: https://doi.org/10.3390/ijms23094631h
Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31(7):1076-85. Doi: 10.1089/thy.2020.0322
Zschäbitz S, Grüllich C. Lenvatinib: A tyrosine kinase inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET. Recent Results Cancer Res. 2018;211:187-98. Available from: https://doi.org/10.1007/978-3-319-91442-8_13
Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, et al. Lenvatinib, a molecule with versatile application: From preclinical evidence to future development in anti-cancer treatment. Cancer Manag Res. 2019;11:3847-60. Available from: http://doi.org/10.2147/CMAR.S188316
Alshehri K, Alqurashi Y, Merdad M, Samargandy S, Daghistani R, Marzouki H. Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review. Cancer Rep (Hoboken). 2022;5(2). Doi: 10.1002/cnr2.1466
Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, et al. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev. 2018;69:164-76. Available from: https://doi.org/10.1016/j.ctrv.2018.06.019
Golingan H, Hunis B, Golding AC, Bimston DN, Harrell RM. Neoadjuvant lenvatinib in advanced unresectable medullary thyroid carcinoma: A case report. AACE Clin Case Rep. 2020;6(2). Doi: 10.4158/ACCR-2019-0365
Tse T, Sehdev S, Seely J, Gravel DH, Clemons M, Cordeiro E, et al. Neoadjuvant chemotherapy in breast cancer: Review of the evidence and conditions that facilitated its use during the global pandemic. Curr Oncol. 2021;28(2):1338-47. Available from: https://doi.org/10.3390/curroncol28020127
Motzer RJ, Taylor MH, Evans TRJ, Okusaka T, Glen H, Lubiniecki GM, et al. Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert Rev Anticancer Ther. 2022;22(4):383-400. Doi:10.1080/14737140.2022.2039123.
Suyama K, Iwase H. Lenvatinib: A promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361. Doi: 10.1177/1073274818789361
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Albert Albert, Christian O. Manginstar, Denny Saleh, Marselus A. Merung
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
